Rubius Therapeutics Inc
RUBY
Morningstar Rating
Skip to Content
Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference
Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer
Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Rubius Therapeutics Appoints Christina Coughlin, M.D., Ph.D., as Chief Medical Officer
Flagship Unveils Newest Pioneering Platform: Ring Therapeutics
Rubius Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress
Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
Rubius Therapeutics Appoints Maiken Keson-Brookes as Chief Legal Officer and Corporate Secretary
Rubius Therapeutics Highlights Preclinical Oncology Data at Society for Immunotherapy of Cancer Annual Meeting and AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Rubius Therapeutics to Announce Third Quarter 2019 Financial Results